Please ensure Javascript is enabled for purposes of website accessibility

Why Agios Pharmaceuticals Shares Jumped 37.8% in January

By Todd Campbell - Updated Mar 8, 2018 at 2:57PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's got some big catalysts coming.

What happened

After filing for FDA approval of its second drug in acute myeloid leukemia (AML) and updating investors on its plans at the J.P. Morgan healthcare conference, shares in Agios Pharmaceuticals (AGIO -1.23%) rallied 37.8% in January, according to S&P Global Market Intelligence.

So what

Agios Pharmaceuticals already has one drug on the market, Idhifa, which is licensed to Celgene (CELG),and it may have a second drug on the market in the same indication later this year if the FDA approves ivosidenib.

A golden capsule resting atop a pile of gold coins.

IMAGE SOURCE: GETTY IMAGES.

Ivosidenib is wholly owned by Agios Pharmaceuticals and, like Idhifa, it targets mutated, metabolic enzymes isocitrate dehydrogenase (IDH). Idhifa targets IDH2 mutations and ivosidenib targets IDH1 -- and together, Agios Pharmaceuticals thinks it can address roughly 10,000 relapsing and recurring AML patients per year.

Studies evaluating the use of these drugs earlier in treatment could expand that addressable market, though. For example, Agios Pharmaceuticals and Celgene plan to begin a phase 3 trial in front-line AML later this year.

There could be an opportunity for these drugs to be used outside of AML, too. Agios Pharmaceuticals is already enrolling a phase 3 trial of ivosidenib in cholangiocarcinoma, a devastating disease without any FDA approved targeted therapies. About 21,000 people are diagnosed with this disease annually, and Agios Pharmaceuticals expects its phase 3 trial will be fully enrolled in 2019. A trial evaluating ivosidenib in low-grade glioma is under way, as well.

Now what

Agios Pharmaceuticals has a well-heeled partner in Celgene, and in the past, Celgene hasn't hesitated to acquire companies with promising drugs in development. For example, it agreed to acquire Juno Therapeutics for $9 billion last month. 

It's a longshot, but perhaps Celgene might be willing to make buy Agios Pharmaceuticals someday, too. Celgene owned nearly 10% of Juno Therapeutics prior to making a bid to buy it outright, and similarly, it owns roughly 12% of Agios Pharmaceuticals stock currently.

If Celgene doesn't acquire it, Agios Pharmaceuticals is still an intriguing biotech to buy. If ivosidenib wins an FDA go-ahead this year, it could add nine figures in annual sales next year. With meaningful sales on deck and an opportunity to expand to other indications, investors' interest in owning Agios Pharmaceuticals shares is understandable. 

 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Celgene Corporation Stock Quote
Celgene Corporation
CELG
Agios Pharmaceuticals, Inc. Stock Quote
Agios Pharmaceuticals, Inc.
AGIO
$22.11 (-1.23%) $0.28

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
317%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.